SCHEMBL15215293

SCHEMBL15215293

CCCCCOC(=O)c1ccccc1NC(C)=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.69
CYP3A4 P08684 2/20 0.69
MAPK1 P28482 2/20 0.69
TP53 P04637 1/20 0.69
ALDH1A1 P00352 9/20 0.68
LMNA P02545 5/20 0.68
KDM4E B2RXH2 6/20 0.67
L3MBTL1 Q9Y468 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
MAPT P10636 2/20 0.67
CYP2C19 P33261 3/20 0.63
CYP1A2 P05177 2/20 0.63
TDP1 Q9NUW8 2/20 0.62
HSD17B10 Q99714 3/20 0.59
POLB P06746 1/20 0.59
HPGD P15428 2/20 0.55
CYP2C9 P11712 1/20 0.55
HTT P42858 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
GAA P10253 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7647082 0.99 ALDH1A1 (0.70) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7627192 0.96 TSHR (0.69) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL4904098 0.85 TSHR (0.73) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7627798 0.85 ALDH1A1 (0.67) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7632457 0.85 ALDH1A1 (0.67) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7635989 0.85 ALDH1A1 (0.67) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7632579 0.85 ALDH1A1 (0.67) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7629086 0.85 ALDH1A1 (0.67) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL7627006 0.85 ALDH1A1 (0.67) TSHRCYP3A4MAPK1TP53ALDH1A1
SCHEMBL3801523 0.85 TSHR (0.64) TSHRCYP3A4MAPK1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315834-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF MEDICON PHARMACEUTICALS, INC. (US) 2014-10-23 US disclosed
US-20140088045-A1 PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT RIGAS BASIL (US) 2014-03-27 US disclosed
US-20130225529-A1 PHOSPHO-ESTER DERIVATIVES AND USES THEREOF MEDICON PHARMACEUTICALS, INC. 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225529-A1 PHOSPHO-ESTER DERIVATIVES AND USES THEREOF PHOSPHO1, PIK3CA, PYGB TSHR 4716/4885CYP3A4 1824/4885MAPK1 370/4885
US-20140315834-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISORDERS, PAIN AND FEVER, SKIN DISORDERS, CANCER AND PRECANCEROUS CONDITIONS THEREOF HMGB1, PTGES, FDPS TSHR 4313/4885CYP3A4 311/4885MAPK1 1792/4885
US-20140088045-A1 PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT TNF, HUNK, NAPRT TSHR 4361/4885CYP3A4 4129/4885MAPK1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.